BA
Balyasny Asset Management L.P. disclosed a 7.9% stake in SABS
Balyasny Asset Management L.P. reported owning 7.9% of SAB Biotherapeutics, Inc. (SABS) (7,225,439 shares) in a Schedule 13G filed Nov 16, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 16, 2026
- Source
- Schedule 13G